表紙
市場調查報告書

全球人微生物叢治療藥市場:藥物,開發平台分析,資金籌措方案,治療用途,10個國家資料,競爭環境:分析與預測 (2019∼2029年)

Global Human Microbiome Therapeutics Market: Focus on Drugs, Pipeline Analysis, Funding Scenario, Therapeutic Application, 10 Countries Data, and Competitive Landscape - Analysis and Forecast, 2019-2029

出版商 BIS Research Inc. 商品編碼 915114
出版日期 內容資訊 英文 193 Pages
商品交期: 最快1-2個工作天內
價格
全球人微生物叢治療藥市場:藥物,開發平台分析,資金籌措方案,治療用途,10個國家資料,競爭環境:分析與預測 (2019∼2029年) Global Human Microbiome Therapeutics Market: Focus on Drugs, Pipeline Analysis, Funding Scenario, Therapeutic Application, 10 Countries Data, and Competitive Landscape - Analysis and Forecast, 2019-2029
出版日期: 2019年10月23日內容資訊: 英文 193 Pages
簡介

全球人微生物叢治療藥市場2019∼2029年,預計以33.0%的年複合成長率擴大。

本報告提供全球人微生物叢治療藥市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介相關資訊彙整。

摘要整理

第1章 市場概要

  • 全球人微生物叢治療藥市場
    • 概要
    • 全球市場方案
    • 市場趨勢
  • 產品製圖

第2章 調查範圍

第3章 調查方法

第4章 產業分析

第5章 競爭環境

  • 概要
  • 主要的發展與策略
    • 聯合和合作
    • 合併和收購
    • 商務擴充
  • 市場佔有率分析
  • 資金籌措方案
  • 政府的配合措施

第6章 各開發階段市場

  • 概要
  • 成藥
  • 第四階段
  • 第三階段

第7章 各適應症市場

  • 概要
  • 消化管,感染疾病
  • 腫瘤、自體免疫疾病
  • 皮膚病
  • 其他

第8章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他各國

第9章 企業簡介

  • 概要
  • 4D Pharma plc
  • AOBiome
  • Finch Therapeutics
  • Ferring Pharmaceuticals
  • Immuron Limited
  • MaaT Pharma
  • Naked Biome
  • OxThera AB
  • Quorum Innovations
  • Ritter Pharmaceuticals
  • Sanofi S.A.
  • Seres Therapeutics, Inc.
  • Synthetic Biologics, Inc.
  • 大正製藥株式會社
  • Vedanta Biosciences, Inc.
  • Whole Biome Inc.
目錄
Product Code: BH171A

"Global Human Microbiome Therapeutics Market to Grow at a CAGR of 33.00% from 2019-2029."

Key Questions Answered in this Report:

  • What are the key features of human microbiome therapeutics which makes them a better choice for the treatment of chronic and non-communicable disease?
  • What is the industry structure of the human microbiome therapeutics market?
  • How did the human microbiome therapeutics market evolve and what is its scope in the future?
  • What are the key development strategies which are implemented by the key players to maintain and capture market share?
  • What are the major market drivers, challenges, and opportunities in the global human microbiome therapeutics market?
  • What are the current leading companies dominating the global human microbiome therapeutics market?
  • What are the regulations pertaining to the global human microbiome therapeutics market?
  • What are the initiatives implemented by different government bodies to reduce the incidence of disease and increase the adoption of human microbiome therapeutics product?
  • What was the market value of the leading segments and sub-segments of the global human microbiome therapeutics market?
  • How is each segment of the global human microbiome therapeutics market expected to grow during the forecast period and what is the revenue expected to be generated by each of the segments by the end of 2029?
  • Which region carries the potential for the significant expansion of key companies for human microbiome therapeutics market?
  • Which products are anticipated to be launched and generate revenue in the forecast period 2019-2029?

Global Human Microbiome Therapeutics Market Forecast, 2019-2029

Human Microbiome Therapeutics Industry Analysis by BIS Research projects the market to grow at a significant CAGR of 33.00% during the forecast period 2019-2029. The human microbiome therapeutics market generated $309.9 million revenue in 2018, in terms of value.

The human microbiome therapeutics growth has been primarily attributed to the major drivers in this market such as increasing prevalence and growing incidence of chronic diseases, growing investments and initiatives in the field of microbiome therapeutics, treatment options with minimal or no side effects, availability of private and government funding, and others. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include product launches, and increasing merger and acquisitions among the industry players. However, there are significant challenges which are restraining the market growth. These challenges include exorbitant cost is required for the clinical trials procedure and stringent regulatory guidelines for the product development and commercialization of the products.

Expert Quote

"With the elucidation of its causative role in cardiometabolic disease and atherosclerosis, the human gut microbiome holds promises as a reservoir of novel potential therapeutic targets as well as novel therapeutic agents, paving a new and exciting avenue in cardiovascular drug discovery and other areas."

Scope of the Market Intelligence on Human Microbiome Therapeutics Market

The human microbiome therapeutics market research provides a holistic view of global market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products for different therapeutic applications in human microbiome therapeutics. In addition, the study also includes exhaustive information on expected commercial launches of the product in the forecast period, perception on the new product launches, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segments, and company, as well as other vital information with respect to global human microbiome therapeutics market.

Market Segmentation

The human microbiome therapeutics market is segmented into three categories, namely, product (by Phases), by disease, and by region.

The product segment includes the segmentation on the basis of different phases of clinical trials, and the disease segment includes, gastrointestinal and infectious diseases, oncology and autoimmune diseases, skin diseases, and neurological diseases.

The region segment is further segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World.

Key Companies in the Global Human Microbiome Therapeutics Market

The key manufacturers who have been contributing significantly to the human microbiome therapeutics market include 4D Pharma plc, Immuron Limited, Sanofi SA., Seres Therapeutics Inc., Synthetic Biologics, Taisho Pharmaceutical, Ritter Pharmaceuticals, AOBiome, Finch Therapeutics, Rebiotix, Inc. (Subsidiary of Ferring Pharmaceutical), Maat Pharma, Ox Thera, Quorum Innovations, Vedanta Biosciences, Whole Biome, and Naked Biome among others.

Table of Contents

Executive Summary

1. Market Overview

  • 1.1. Global Human Microbiome Therapeutics Market
    • 1.1.1. Overview
    • 1.1.2. Global Market Scenario
    • 1.1.3. Market Dynamics
  • 1.2. Product Mapping

2. Scope of the Work

  • 2.1. Overview: Report Scope
  • 2.2. Segmentation of the Global Human Microbiome Therapeutics Market
  • 2.3. Assumptions and Limitations
  • 2.4. Key Questions Answered in the Report
  • 2.5. Base Year and Forecast Period

3. Research Methodology

  • 3.1. Overview: Report Methodology

4. Industry Analysis

  • 4.1. Regulatory Scenario
  • 4.2. Regulatory Designations
  • 4.3. Regulatory requirements for Live Biotherapeutic Products (LBPs)
  • 4.4. Patent Analysis

5. Competitive Landscape

  • 5.1. Overview
  • 5.2. Key Developments and Strategies
    • 5.2.1. Collaborations and Partnerships
    • 5.2.2. Mergers and Acquisitions
    • 5.2.3. Business Expansions
  • 5.3. Market Share Analysis
  • 5.4. Funding Scenario
  • 5.5. Government Initiatives

6. Global Human Microbiome Therapeutics Market (by Development Phase)

  • 6.1. Overview
  • 6.2. Commercialized Drugs
  • 6.3. Drugs in Phase 4
  • 6.4. Drugs in Phase 3

7. Global Human Microbiome Therapeutics Market (by Indication)

  • 7.1. Overview
  • 7.2. Gastrointestinal and Infectious Diseases
  • 7.3. Oncology and Autoimmune Diseases
  • 7.4. Skin Diseases
  • 7.5. Others

8. Global Human Microbiome Therapeutics Market (by Region)

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. Overview
    • 8.2.2. U.S.
    • 8.2.3. Canada
  • 8.3. Europe
    • 8.3.1. Overview
    • 8.3.2. France
    • 8.3.3. Sweden
    • 8.3.4. Germany
    • 8.3.5. U.K.
    • 8.3.6. Rest-of-Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Overview
    • 8.4.2. Japan
    • 8.4.3. Australia
    • 8.4.4. China
    • 8.4.5. India
    • 8.4.6. Rest-of-Asia-Pacific
  • 8.5. Rest-of-the-World
    • 8.5.1. Overview
    • 8.5.2. Middle East and Africa
    • 8.5.3. Latin America

9. Company Profiles

  • 9.1. Overview
  • 9.2. 4D Pharma plc
    • 9.2.1. Company Overview
    • 9.2.2. Role of 4D Pharma plc in the Global Human Microbiome Therapeutics Market
    • 9.2.3. Financials
    • 9.2.4. SWOT Analysis
  • 9.3. AOBiome
    • 9.3.1. Company Overview
    • 9.3.2. Role of AOBiome in the Global Human Microbiome Therapeutics Market
    • 9.3.3. SWOT Analysis
  • 9.4. Finch Therapeutics
    • 9.4.1. Company Overview
    • 9.4.2. Role of Finch Therapeutics in the Global Human Microbiome Therapeutics Market
    • 9.4.3. SWOT Analysis
  • 9.5. Ferring Pharmaceuticals
    • 9.5.1. Company Overview
    • 9.5.2. Rebiotix Inc. (Subsidiary of Ferring Pharmaceuticals): Company Overview
    • 9.5.3. Role of Rebiotix Inc. in the Global Human Microbiome Therapeutics Market
    • 9.5.4. SWOT Analysis
  • 9.6. Immuron Limited
    • 9.6.1. Company Overview
    • 9.6.2. Role of Immuron in the Global Human Microbiome Therapeutics Market
    • 9.6.3. Financials
    • 9.6.4. SWOT Analysis
  • 9.7. MaaT Pharma
    • 9.7.1. Company Overview
    • 9.7.2. Role of MaaT Pharma in the Global Human Microbiome Therapeutics Market
    • 9.7.3. SWOT Analysis
  • 9.8. Naked Biome
    • 9.8.1. Company Overview
    • 9.8.2. Role of Naked Biome in Human Microbiome Therapeutics Market
    • 9.8.3. SWOT Analysis
  • 9.9. OxThera AB
    • 9.9.1. Company Overview
    • 9.9.2. Role of OxThera AB in the Global Human Microbiome Therapeutics Market
    • 9.9.3. SWOT Analysis
  • 9.10. Quorum Innovations
    • 9.10.1. Company Overview
    • 9.10.2. Role of Quorum Innovations, LLC in Human Microbiome Therapeutics Market
    • 9.10.3. SWOT Analysis
  • 9.11. Ritter Pharmaceuticals
    • 9.11.1. Company Overview
    • 9.11.2. Role of Ritter Pharmaceuticals in the Global Human Microbiome Therapeutics Market
    • 9.11.3. Financials
    • 9.11.4. SWOT Analysis
  • 9.12. Sanofi S.A.
    • 9.12.1. Company Overview
    • 9.12.2. Role of Sanofi S.A. in the Global Human Microbiome Therapeutics Market
    • 9.12.3. Financials
      • 9.12.3.1. Key Insights About the Financial Health of the Company
    • 9.12.4. SWOT Analysis
  • 9.13. Seres Therapeutics, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Role of Seres Therapeutics, Inc. in the Global Human Microbiome Therapeutics Market
    • 9.13.3. Financials
      • 9.13.3.1. Key Insights About Financial Health of the Company
    • 9.13.4. SWOT Analysis
  • 9.14. Synthetic Biologics, Inc.
    • 9.14.1. Company Overview
    • 9.14.2. Role of Synthetic Biologics, Inc. in the Global Human Microbiome Therapeutics Market
    • 9.14.3. Financials
    • 9.14.4. SWOT Analysis
  • 9.15. Taisho Pharmaceutical
    • 9.15.1. Company Overview
    • 9.15.2. Biofermin Pharmaceutical Co. Ltd. (Subsidiary of Taisho Pharmaceutical) Company Overview
    • 9.15.3. Role of Taisho Pharmaceutical in Global Human Microbiome Therapeutics Market
    • 9.15.4. Financial
      • 9.15.4.1. Key Insights about the Financial Health of the Company
    • 9.15.5. SWOT Analysis
  • 9.16. Vedanta Biosciences, Inc.
    • 9.16.1. Company Overview
    • 9.16.2. Role of Vedanta Biosciences, Inc. in the Global Human Microbiome Therapeutics Market
    • 9.16.3. SWOT Analysis
  • 9.17. Whole Biome Inc.
    • 9.17.1. Company Overview
    • 9.17.2. Role of Whole Biome Inc. in the Global Human Microbiome Therapeutics Market
    • 9.17.3. SWOT Analysis

List of Tables

  • Table 1.1: Product Mapping Matrix by Company (Development Phase)
  • Table 1.2: No. of Products by Developmental Phase
  • Table 1.3: No. of Products by Indications
  • Table 4.1: Regulatory Authorities/Associations/Consortiums of the Global Human Microbiome Therapeutics Market
  • Table 5.1: Ranking of Key Potential Players (2020-2029)
  • Table 5.2: Funding Scenario
  • Table 5.3: Government Initiatives in the Human Microbiome Therapeutics
  • Table 6.1: Global Human Microbiome Therapeutics Market (by Development Phase), 2017-2029
  • Table 6.2: Commercialized Products, 2017 and 2018
  • Table 6.3: Products in Phase 4, 2018
  • Table 6.4: Products in Phase 3, 2018
  • Table 7.1: Global Human Microbiome Therapeutics Market (by Indication), 2017-2029
  • Table 8.1: EU Funding of Microbiome Research Under FP7 and H2020

List of Figures

  • Figure 1: Antibiotic Resistance (%) in OECD Countries, 2014
  • Figure 2: Global Human Microbiome Modulators Market Snapshot
  • Figure 3: Global Human Microbiome Therapeutics, 2018-2029
  • Figure 4: Global Human Microbiome Therapeutics, 2018-2029 (Three Scenarios)
  • Figure 5: Market Drivers and Challenges of Global Human Microbiome Therapeutics Market
  • Figure 6: Share of Key Developments and Strategies, January 2016-August 2019
  • Figure 7: Pipeline Analysis
  • Figure 8: Global Human Microbiome Therapeutics Market (by Indication), 2023 and 2029
  • Figure 9: Global Human Microbiome Therapeutics Market (by Region), 2018
  • Figure 1.1: Evolution of Human Microbiome Modulators
  • Figure 1.2: Mechanisms of Action of Human Microbiome Therapeutic Drugs
  • Figure 1.3: Number of Drugs in Active Development, 2011-2017
  • Figure 1.4: Global Human Microbiome Therapeutics Market, 2018-2029
  • Figure 1.5: Global Human Microbiome Therapeutics, 2018-2029 (Three Scenario)
  • Figure 1.6: Drivers and Challenges of Global Human Microbiome Therapeutics Market
  • Figure 2.1: Global Human Microbiome Therapeutics Market Segmentation
  • Figure 3.1: Global Human Microbiome Therapeutics Market Research Methodology
  • Figure 3.2: Primary Research
  • Figure 3.3: Secondary Research
  • Figure 3.4: Data Triangulation
  • Figure 3.5: Bottom-up Approach (Segment-wise Analysis)
  • Figure 3.6: Assumptions and Limitations
  • Figure 4.1: Chemistry, manufacturing, and control (CMC) information of LBPs by FDA
  • Figure 4.2: Patent Landscape of Human Microbiome Therapeutics Market
  • Figure 5.1: Competitive Landscape (January 2016-August 2019)
  • Figure 5.2: Share of Key Developments and Strategies, January 2016-August 2019
  • Figure 5.3: Collaboration and Partnership (by Company), January 2016 and August 2019
  • Figure 5.4: Merger and Acquisition (by Company), January 2016 and August 2019
  • Figure 5.5: Business Expansion (by Company), January 2016 and August 2019
  • Figure 5.6: Market Share Analysis of Global Human Microbiome Therapeutics Market, 2017 and 2018
  • Figure 6.1: Global Human Microbiome Therapeutics Market, 2017-2029
  • Figure 6.2: Global Human Microbiome Therapeutics Market (by Commercialized Drug), 2017-2029
  • Figure 6.3: Global Human Microbiome Therapeutics Market (by Phase 4 Drugs), 2021-2029
  • Figure 6.4: Global Human Microbiome Therapeutics Market (by Phase 3 Drug), 2023-2029
  • Figure 7.1: Number of Pipeline Candidates for Gastrointestinal and Infectious Disease Indications
  • Figure 7.2: Global Human Microbiome Therapeutics Market (by Gastrointestinal and Infectious Disease),
  • Figure 7.3: Number of Pipeline Candidates for Oncology and Autoimmune Diseases
  • Figure 7.4: Global Human Microbiome Therapeutics Market (by Oncology and Autoimmune Disease),2021-2029
  • Figure 7.5: Number of Pipeline Candidates for Gastrointestinal and Infectious Disease Indications
  • Figure 7.6: Global Human Microbiome Therapeutics Market (by Skin Diseases), 2023-2029
  • Figure 7.7: Global Human Microbiome Therapeutics Market (by Other Diseases), 2023-2029
  • Figure 8.1: Global Human Microbiome Therapeutics Market (by Region), 2018
  • Figure 8.2: North America: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.3: North America: Market Dynamics
  • Figure 8.4: North America: Human Microbiome Therapeutics Market (by Country), 2018 and 2029
  • Figure 8.5: U.S.: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.6: Canada: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.7: Europe: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.8: Europe: Market Dynamics
  • Figure 8.9: Europe: Human Microbiome Therapeutic Market (by Country), 2018 and 2029
  • Figure 8.10: France: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.11: Sweden: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.12: Germany: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.13: U.K.: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.14: Rest-of-Europe: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.15: Asia-Pacific: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.16: Asia-Pacific: Market Dynamics
  • Figure 8.17: Asia-Pacific: Human Microbiome Therapeutics Market (by Country), 2018 and 2029
  • Figure 8.18: Japan: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.19: Australia: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.20: China: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.21: India: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.22: Rest-of-Asia-Pacific: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.23: Rest-of-the-World: Human Microbiome Therapeutics Market, 2018-2029
  • Figure 8.24: Rest-of-the-World: Market Dynamics
  • Figure 8.25: Rest-of-the-World: Human Microbiome Therapeutics Market (by Region), 2018 and 2029
  • Figure 9.1: Total Number of Companies Profiled
  • Figure 9.2: 4D Pharma plc: Overall Product Portfolio
  • Figure 9.3: 4D Pharma plc.: Overall Financials, 2016-2018
  • Figure 9.4: 4D Pharma plc: SWOT Analysis
  • Figure 9.5: AOBiome.: Overall Product Portfolio
  • Figure 9.6: AOBiome: SWOT Analysis
  • Figure 9.7: Finch Therapeutics: Overall Product Portfolio
  • Figure 9.8: Finch Therapeutics: SWOT Analysis
  • Figure 9.9: Rebiotix Inc.: Overall Product Portfolio
  • Figure 9.10: Rebiotix Inc.: SWOT Analysis
  • Figure 9.11: Immuron: Overall Product Portfolio
  • Figure 9.12: Immuron: Overall Financials, 2016-2018
  • Figure 9.13: Immuron: Research and Development Expenditure, 2016-2018
  • Figure 9.14: Immuron: SWOT Analysis
  • Figure 9.15: MaaT Pharma.: Overall Product Portfolio
  • Figure 9.16: MaaT Pharma: SWOT Analysis
  • Figure 9.17: Naked Biome: Overall Product Portfolio
  • Figure 9.18: Naked Biome: SWOT Analysis
  • Figure 9.19: OxThera AB: Overall Product Portfolio
  • Figure 9.20: OxThera AB: SWOT Analysis
  • Figure 9.21: Quorum Innovations, LLC: Overall Product Portfolio
  • Figure 9.22: Quorum Innovations, LLC: SWOT Analysis
  • Figure 9.23: Ritter Pharmaceuticals: Overall Product Portfolio
  • Figure 9.24: Ritter Pharmaceuticals: Overall Financials, 2016-2018
  • Figure 9.25: Ritter Pharmaceuticals: SWOT Analysis
  • Figure 9.26: Sanofi S.A.: Overall Product Portfolio
  • Figure 9.27: Sanofi S.A.: Overall Financials, 2016-2018
  • Figure 9.28: Sanofi S.A.: Revenue (by Segment), 2016-2018
  • Figure 9.29: Sanofi S.A.: Region Revenue (by Consumer Health Segment), 2016-2018
  • Figure 9.30: Sanofi S.A.: Consumer Healthcare Revenue (by Sub-Segment), 2016-2018
  • Figure 9.31: Sanofi S.A.: Research and Development Expenditure, 2016-2018
  • Figure 9.32: Sanofi S.A.: SWOT Analysis
  • Figure 9.33: Seres Therapeutics, Inc.: Overall Product Portfolio
  • Figure 9.34: Seres Therapeutics, Inc.: Overall Financials, 2016-2018
  • Figure 9.35: Seres Therapeutics Inc.: R&D Expenditure, 2016-2018
  • Figure 9.36: Seres Therapeutics Inc.: SWOT Analysis
  • Figure 9.37: Synthetic Biologics, Inc.: Overall Product Portfolio
  • Figure 9.38: Synthetic Biologics, Inc.: Overall Financials, 2016-2018
  • Figure 9.39: Synthetic Biologics, Inc.: SWOT Analysis
  • Figure 9.40: Taisho Pharmaceutical Co., Ltd.: Overall Product Portfolio
  • Figure 9.41: Taisho Pharmaceutical Co., Ltd.: Overall Financials, 2016-2018
  • Figure 9.42: Taisho Pharmaceutical Co., Ltd. (by Segment), 2016-2018
  • Figure 9.43: Taisho Pharmaceutical Co., Ltd.: Biofermin Sales, 2016-2018
  • Figure 9.44: Taisho Pharmaceutical Co., Ltd. (by Region), 2016-2018
  • Figure 9.45: Taisho Pharmaceutical Co., Ltd.: R&D Expenditure, 2016-2018
  • Figure 9.46: Taisho Pharmaceutical Co., Ltd.: SWOT Analysis
  • Figure 9.47: Vedanta Biosciences, Inc.: Overall Product Portfolio
  • Figure 9.48: Vedanta Biosciences, Inc.: SWOT Analysis
  • Figure 9.49: Whole Genome Inc.: Overall Product Portfolio
  • Figure 9.50: Whole Biome Inc.: SWOT Analysis